COAG
Hemab Therapeutics Holdings, Inc. (NASDAQ)
Healthcare — Biotechnology
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $1.52B |
| P/E Ratio (TTM) | - |
| Forward P/E | -13.28 |
| EPS (TTM) | $-10.13 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.66 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $41.40 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 62.7 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $38.87 |
| 52-Week Low | $23.00 |
| 50-Day Avg | $27.71 |
| 200-Day Avg | $27.71 |
| Avg Volume | 356.0K |
| Volume | 203.3K |
Performance Analysis
BULLISHCOAG shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report